ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
September 18, 2018AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate) versus dual combination therapies Bevespi Aeros
Pharma Sources Insight January 2025
